European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1
Community Register of medicinal products
Community register of orphan medicinal products | GRANTED |
Product information |
R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea
| EU orphan designation number: | EU/3/07/452
|
| Active ingredient: | R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea |
| Indication: | Treatment of gastric carcinoid |
| Sponsor: | Trio Medicines Ltd
Pavilion View, 19 New Road, Brighton, East Sussex, BN1 1EY, United Kingdom |
Public summary of scientific opinion
European Commission procedures
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 19/06/2007 | Centralised Orphan - Designation | EMEA/OD/014/07 | (2007)3028 of 14/06/2007 |